Team
Our team is committed to developing transformative therapies that decrease the burden of disease and increase healthspan on a population-level scale
Leadership
Board
Advisors
Kristen Fortney, PhD
Co-Founder, CEO
Eric Morgen, MD
Co-Founder, COO
Paul Rubin, MD
CMO & EVP, Research
Peng Leong, PhD, MBA
Chief Business Officer & Therapeutic Area Head, Brain Aging
Ann Neale
Chief Development Officer
Dov Goldstein, MD, MBA
Chief Financial Officer
BJ Sullivan, PhD
Chief Strategy Officer
Patrick Martin, MD
SVP, Clinical Science
Julie Gammelgard
SVP, People
Sabine Vukelich, PhD
SVP, Regulatory Affairs & QA
Rusty Montgomery, PhD
SVP, Research
Robert Hughes, PhD
Senior Fellow
Chris Patil, PhD
VP, Media
Ralph Scarborough
VP, Finance & Accounting
Sanjeev Kothari, PhD
VP, CMC
Naisha Shah, PhD
VP, Data Science
Yan Wang
VP, Translational Aging Biology
Kristen Fortney, PhD
Co-Founder, CEO
Eric Morgen, MD
Co-Founder, COO
Vijay Pande, PhD
Professor at Stanford, Partner at a16z
Jason Coloma, PhD, MBA
Independent Director
Rekha Hemrajani, MBA
Independent Director
George Hartman, PhD
Sr.Advisor, Chemistry
Klaus Klumpp, PhD
Sr.Advisor, Drug Discovery
Elad Gil, PhD
Advisor, Biotechnology
Joe Betts-LaCroix
Advisor, Biotechnology
Eric Verdin, MD
Advisor, Aging
William J. Evans, PhD
Advisor, Muscle Aging
Mark Perrone, PhD
Advisor, Pharmacology
Peter Dilaura
Advisor, Biotechnology
Pankaj Agarwal, PhD
Advisor, Drug Discovery Bioinformatics
Bradley Willcox, MD
Advisor, Biobanks
Tõnu Esko, PhD
Advisor, Biobanks
Kristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.
